作者
Georg Semmler,Sonia Alonso López,NULL AUTHOR_ID,NULL AUTHOR_ID,Elton Dajti,Marie Griemsmann,NULL AUTHOR_ID,Lukas Burghart,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Maria Luisa Gutiérrez García,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,D. Ecker,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Juan Antonio Carbonell-Asíns,Michael Gschwantler,Francesco Paolo Russo,NULL AUTHOR_ID,NULL AUTHOR_ID,Thomas Reiberger,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID
摘要
Around 750,000 patients per year will be cured of HCV infection until 2030. Those with compensated advanced chronic liver disease remain at risk for hepatic decompensation and de novo HCC. Algorithms have been developed to stratify risk early after cure; however, data on long-term outcomes and the prognostic utility of these risk stratification algorithms at later time points are lacking.